The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Curious as to what will happen to your shares with a Nasdaq listing. Does which broker you use make a difference?
I.e. will your broker automatically convert your shares to the new Nasdaq stock, or will your broker sell your shares and give you cash
Just wondering whether I should think about getting a new broker
11th Aug 2021: First Patient Dosed in AVA6000 Phase 1 Trial.
The dose escalation phase is anticipated to complete by Q2 2022 followed by completion of the dose expansion phase by Q2 2023.
176 days later.
3rd Feb 2022: Dose escalation in the phase I trial of AVA6000
Avacta's Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the first cohort dosed with AVA6000 at 80mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 120mg/m2.
146 days later.
29th June 2022: Second dose escalation in phase 1 trial of AVA6000
Avacta's Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the second cohort dosed with AVA6000 at 120mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 160mg/m2.
64 days later
1st Sep 2022: Phase I study of AVA6000 advances to fourth cohort
Avacta's Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the third cohort dosed with AVA6000 at 160mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 200mg/m2.
It's now been 95 days since 1st September 2022. Avacta originally advised completion of the dose escalation phase by Q2 2023. Surely we can expect the next RNS to be regarding a fifth cohort through Q1 2023, with possibly a sixth cohort at 240mg/m2 to bring conclusion on P1a data in Q2 2023.
Sorry all of this is repeating things. I’ve not really being monitoring things this week. Can someone summarise this weeks events?
Last time I checked we have dose escalation on AVA6000 and things were looking good.
What’s changed since as I don’t see any RNS, bad road show?
https://www.gov.uk/guidance/coronavirus-covid-19-testing-for-people-travelling-to-england
Test providers and type of test
You will need to find a test provider. You must make sure that the test provider can meet the standards for pre-departure testing.
The test must meet performance standards of =97% specificity, =80% sensitivity at viral loads above 100,000 copies/ml.
This could include tests such as:
a nucleic acid test, including a polymerase chain reaction (PCR) test or derivative technologies, including loop-mediated isothermal amplification (LAMP) tests
an antigen test, such as a test from a lateral flow device
This year hosts a key inflection point for holders with human trials. Questions waiting to be answered such as whether Affimers will generate an unwanted immune reaction and subsequently be neutralised in the body, or whether they are therapeutically safe and if there inherently short half-life will limit efficacy.
Positive certainty on these questions will open the doors to a mcap many multiples of where we are, in the billions
With diagnostics pretty much a certain. The question of whether affimers are safe in the body is the critical question for me when it comes to therapeutics. Once proved they are safe, then this is stock lifetime hold for me
Biomedical development**
https://twitter.com/738Pilot/status/1387454689554350082?s=20
https://www.medusa19.com/
We are ready for Europe